Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GED-0507-34-Levo in active ulcerative colitis
2016-001684-36Phase 2Terminated
- Sponsor
- PPM Services
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ged-0507-34-levo in autoimmune colitis (3 arms), sponsored by PPM Services. Primary endpoint: Clinical remission at Week 8 by Modified Mayo score. Started Jul 2016; status: terminated.
02
Drugs
ged-0507-34-levo
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-001684-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001684-36.